Brief: United Therapeutics Announces Positive Results From Phase 1 Study Of Miroliverelap In Patients With Acute Liver Failure
26/01/2026 12:02
Jan 26 (Reuters) - United Therapeutics Corp UTHR.O: UNITED THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 1 STUDY OF MIROLIVERELAP® IN PATIENTS WITH ACUTE LIVER FAILURE UNITED THERAPEUTICS CORP - STUDY MET PRIMARY ENDPOINT OF SURVIVAL DURING TREATMENT UNITED THERAPEUTICS CORP - NO UNEXPECTED SERIOUS ADVERSE EVENTS REPORTED Source text: ID:nBw3mnsnza Further company coverage: UTHR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug